(Q34000188)

English

MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

6

object named as

Xin-Lan Luo

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

3

object named as

Dong-Lan Luo

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

author name string

Li-Xu Yan

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Yan-Hui Liu

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Fen Zhang

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Yu Cheng

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Jie Xu

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Jie Cheng

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Heng-Guo Zhuang

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

4 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

e104068

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

copyright license

Creative Commons Attribution 4.0 International

4 August 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Phosphorylated IκBα predicts poor prognosis in activated B-cell lymphoma and its inhibition with thymoquinone induces apoptosis via ROS release

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Clinicopathologic analysis of localized nasal/paranasal diffuse large B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Pr

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4121314

5 July 2018

Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

Prognostic evaluation of immunohistochemical profiles in diffuse large B-cell lymphoma: a Chinese study.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

Outcome of R-CHOP or CHOP regimen for germinal center and nongerminal center subtypes of diffuse large B-cell lymphoma of Chinese patients

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0104068

21 January 2018

MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/25090026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differences in germinal centre and non-germinal center phenotype in gastric and intestinal diffuse large B-cell lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/25090026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MYCtranslocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation

1 reference

https://pubmed.ncbi.nlm.nih.gov/25090026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

1 reference

https://pubmed.ncbi.nlm.nih.gov/25090026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diffuse large B-cell lymphoma in Chinese patients: immunophenotypic and cytogenetic analyses of 124 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/25090026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Impact of immunochemotherapy on prognostic factors in diffuse large B-cell lymphoma patients]

1 reference

https://pubmed.ncbi.nlm.nih.gov/25090026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation

1 reference

https://pubmed.ncbi.nlm.nih.gov/25090026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low incidence of BCL-6 gene alterations for diffuse large B-cell lymphomas in Taiwan Chinese

1 reference

https://pubmed.ncbi.nlm.nih.gov/25090026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25090026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/25090026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25090026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0104068

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

2014PLoSO...9j4068Y

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34000188&oldid=2041304581"